169 related articles for article (PubMed ID: 23668227)
1. QSAR methods for the discovery of new inflammatory bowel disease drugs.
García-Domenech R; Gálvez-Llompart M; Zanni R; Recio MC; Gálvez J
Expert Opin Drug Discov; 2013 Aug; 8(8):933-49. PubMed ID: 23668227
[TBL] [Abstract][Full Text] [Related]
2. Advances in the molecular modeling and quantitative structure-activity relationship-based design for antihistamines.
Galvez J; Galvez-Llompart M; Zanni R; Garcia-Domenech R
Expert Opin Drug Discov; 2013 Mar; 8(3):305-17. PubMed ID: 23289365
[TBL] [Abstract][Full Text] [Related]
3. Molecular topology as a novel approach for drug discovery.
Gálvez J; Gálvez-Llompart M; García-Domenech R
Expert Opin Drug Discov; 2012 Feb; 7(2):133-53. PubMed ID: 22468915
[TBL] [Abstract][Full Text] [Related]
4. Latest advances in molecular topology applications for drug discovery.
Zanni R; Galvez-Llompart M; García-Domenech R; Galvez J
Expert Opin Drug Discov; 2015; 10(9):945-57. PubMed ID: 26134383
[TBL] [Abstract][Full Text] [Related]
5. QSAR studies in the discovery of novel type-II diabetic therapies.
Abuhammad A; Taha MO
Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR and molecular docking for the discovery of ketolide derivatives.
Ruan ZX; Huangfu DS; Xu XJ; Sun PH; Chen WM
Expert Opin Drug Discov; 2013 Apr; 8(4):427-44. PubMed ID: 23441865
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationship: promising advances in drug discovery platforms.
Wang T; Wu MB; Lin JP; Yang LR
Expert Opin Drug Discov; 2015 Dec; 10(12):1283-300. PubMed ID: 26358617
[TBL] [Abstract][Full Text] [Related]
8. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
9. Modern drug discovery for inflammatory bowel disease: The role of computational methods.
Johnson TO; Akinsanmi AO; Ejembi SA; Adeyemi OE; Oche JR; Johnson GI; Adegboyega AE
World J Gastroenterol; 2023 Jan; 29(2):310-331. PubMed ID: 36687123
[TBL] [Abstract][Full Text] [Related]
10. Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery.
Speck-Planche A; Cordeiro MN
Expert Opin Drug Discov; 2015 Mar; 10(3):245-56. PubMed ID: 25613725
[TBL] [Abstract][Full Text] [Related]
11. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
12. Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents.
Ambure P; Roy K
Expert Opin Drug Discov; 2014 Jun; 9(6):697-723. PubMed ID: 24754675
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the use of open-source software applications in drug discovery.
Geldenhuys WJ; Gaasch KE; Watson M; Allen DD; Van der Schyf CJ
Drug Discov Today; 2006 Feb; 11(3-4):127-32. PubMed ID: 16533710
[TBL] [Abstract][Full Text] [Related]
14. New insights toward the discovery of antibacterial agents: multi-tasking QSBER model for the simultaneous prediction of anti-tuberculosis activity and toxicological profiles of drugs.
Speck-Planche A; Kleandrova VV; Cordeiro MN
Eur J Pharm Sci; 2013 Mar; 48(4-5):812-8. PubMed ID: 23376211
[TBL] [Abstract][Full Text] [Related]
15. Progress in structure-based drug design against influenza A virus.
Du QS; Wei H; Huang RB; Chou KC
Expert Opin Drug Discov; 2011 Jun; 6(6):619-31. PubMed ID: 22646152
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 1A1-mediated anticancer drug discovery: in silico findings.
Nandekar PP; Sangamwar AT
Expert Opin Drug Discov; 2012 Sep; 7(9):771-89. PubMed ID: 22716293
[TBL] [Abstract][Full Text] [Related]
17. QSAR of phytochemicals for the design of better drugs.
Kar S; Roy K
Expert Opin Drug Discov; 2012 Oct; 7(10):877-902. PubMed ID: 22897485
[TBL] [Abstract][Full Text] [Related]
18. Rational drug design for anti-cancer chemotherapy: multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents.
Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
Bioorg Med Chem; 2012 Aug; 20(15):4848-55. PubMed ID: 22750007
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists.
Hagiwara Y; Ohno K; Kamohara M; Takasaki J; Watanabe T; Fukunishi Y; Nakamura H; Orita M
Expert Opin Drug Discov; 2013 Aug; 8(8):951-64. PubMed ID: 23682717
[TBL] [Abstract][Full Text] [Related]
20. Descriptors for antimicrobial peptides.
Jenssen H
Expert Opin Drug Discov; 2011 Feb; 6(2):171-84. PubMed ID: 22647135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
